{
    "prompt": "5.1. Inclusion Criteria\nThese are your instructions:General Points:\nThese are your instructions:* List the criteria necessary for participation in the study. Ensure that each criterion can be easily assessed on the basis of measurable data and answered with yes/no responses.\nThese are your instructions:* When choosing inclusion criteria, consider that study participants should be representative of the patient population to which the results will be generalized.\nThese are your instructions:* The choice of the study population in a Phase 2 or Phase 3 clinical study should reflect the intended use of the intervention. This is particularly relevant for planning multiregional studies and for the range of subgroups that may be relevant to evaluate. \nThese are your instructions:* If measures to enrich the study population for prespecified subgroups of interest are used, they should be described here.\nThese are your instructions:* In general, laboratory results required for eligibility should be listed as inclusion criteria rather than exclusion criteria.\nThese are your instructions:* The use of double negatives should be avoided (eg, no indication of prior noncompliance with the intervention regimen).\nThese are your instructions:* As applicable, the inclusion criteria should take into consideration the medical device component for DDC products and the usability aspects for the targeted population. \nThese are your instructions:* Specify any PRO-specific eligibility criteria (eg, language/reading requirements or pre\u001erandomization completion of PRO). If PROs will not be collected in the entire study sample, provide a rationale and describe the recruitment method for obtaining the PRO subsample.\nThese are your instructions:Participants are eligible to be included in the study only if all of the following criteria apply:\nThese are your instructions:Age\nThese are your instructions:<Start of suggested text>\nThese are your instructions:1. Participant must be [18] [or the legal age of consent in the jurisdiction in which the study is taking place] to [X] years of age inclusive, at the time of signing the informed consent.\nThese are your instructions:<End of suggested text>\nThese are your instructions:Type of Participant and Disease Characteristics\nThese are your instructions:For studies in healthy volunteers, begin with this criterion.\nThese are your instructions:<Start of suggested text>\nThese are your instructions:2. Participants who are overtly healthy as determined by medical evaluation including [medical history, physical examination, laboratory tests, and cardiac monitoring].\nThese are your instructions:OR\nThese are your instructions:3. Participants who are [insert criteria]\nThese are your instructions:* For studies in patients, provide disease\u001erelated considerations: standard, accepted diagnostic criteria (consider supplying laboratory reference ranges or clinical diagnostic criteria in an appendix). Include duration/severity of disease or disorder if appropriate.\nThese are your instructions:* When appropriate, specify a realistic and pragmatic inclusion range for each test or marker of interest. Take into consideration any known assay variance or error rate as well as biological variation to avoid creating protocol violation issues.\nThese are your instructions:* For details on rescreening, insert a cross-reference to Section 5.4, if appropriate.\nThese are your instructions:* Check whether additional information associated with the disease area can be found in the therapeutic area libraries.\nThese are your instructions:<End of suggested text>\nThese are your instructions:Weight\nThese are your instructions:Consider whether any restriction on weight or BMI is needed for this study intervention/stage of development and delete if not required. \nThese are your instructions:<Start of suggested text>\nThese are your instructions:4. Body weight within [insert range including units] and BMI within the range [X  X] kg/m2 (inclusive)\nThese are your instructions:<End of suggested text>\nThese are your instructions:Sex and Contraceptive/Barrier Requirements\nThese are your instructions:All references to male & female pertain to sex assigned at birth, most often based on the infants physical characteristics.\nThese are your instructions:5. [male and/or female] assigned at birth, inclusive of all gender identities.\nThese are your instructions:If there are no contraceptive requirements in the study, remove the statement Contraceptive use by participant and participant partners . Modify as appropriate based upon participant inclusion.\nThese are your instructions:<Start of common text>\nThese are your instructions:Contraceptive use by [participants or participant partners] should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\nThese are your instructions:Male participants:\nThese are your instructions:See participant libraries for common text to include here.\nThese are your instructions:Female participants:\nThese are your instructions:See participant libraries for common text to include here.\nThese are your instructions:<End of common text>\nThese are your instructions:Informed Consent\nThese are your instructions:<Start of common text>\nThese are your instructions:6. Signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\nThese are your instructions:<End of common text>\nThese are your instructions:Other Inclusion Criteria\nThese are your instructions:7. Enter Other Inclusion Criteria\nThese are your instructions:MANDATORY SPONSOR INPUTS FOR STUDY PROTOCOL GENERATION\nSponsor Name FADOI /BMS/PFIZER\nStudy Acronym (if available):  CARAVAGGIO Study\nTested IMP :Apixaban\nComparative drug: Dalteparin\nStudy Type Interventional\nSe Study Type = Interventional:\nInterventional Study Phase Phase IIIb\nStudy Design International, multicenter, Prospective Randomized Open Blinded End-point (PROBE), where both patients and investigators are aware of the treatment assignments, but the outcome assessment is blindedactive-controlled, event-driven, Phase IIIB clinical study comparing the efficacy and safety of Apixaban to the SOC Dalteparin in for the treatment of venous thromboembolism in patients with cancer.\nAim of the study: The aim of this study is to assess whether oral apixaban is non-inferior to the subcutaneous low molecular weight (LMWH) dalteparin for the treatment of newly diagnosed proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in patients with cancer.\nTarget Disease: VTE (DVT/PE) in cancer patients\nType of Randomization: Patients will be randomized on a 1:1 basis (permuted blocks of four) to receive either apixaban or dalteparin in an open-label fashion.\nRandomization should be centralized and stratified by:\n1) symptomatic vs. unsuspected VTE\n2) active cancer vs. history of cancer\nTested drugs and dosages \nApixaban group: orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)\nDalteparin group: subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months (total period of treatment: six months). The maximum daily dose allowed for dalteparin is 18,000IU.\nApixaban 5mg will be supplied by the Promoter as film-coated tablets.\nDalteparin will be supplied by the Promoter as single-use pre-filled syringes.\nStudy Scheduled Patient’s Visits\nThe study should foresee the following scheduled visits: at enrollment, at 4 weeks, at 3 months, at 6 months, at the end of study treatment whenever it occurs, and at 7 months from randomization.\nAdditional visits will be performed if new symptoms and/or signs of VTE or major bleeding develop. A clinical examination and objective tests will be performed if the patient develops symptoms or signs suggestive of recurrent VTE.\nStudy Objectives \nPrimary efficacy outcome:\nobjectively confirmed recurrent VTE occurring during the study period, that means the composite of:\n• proximal DVT of the lower limbs (symptomatic or unsuspected)\n• DVT of the upper limb (symptomatic)\n• PE (symptomatic or unsuspected)\nSecondary efficacy outcomes:\n• the individual components of the primary efficacy outcome;\n• symptomatic recurrence of VTE;\n• all cause death;\n• the composite of primary efficacy outcome plus major bleeding;\n• the composite of primary efficacy outcome plus major bleeding plus all cause death;\n• the composite of primary efficacy outcome plus all cause death;\n• any major cardiovascular event, fatal or non-fatal (including acute myocardial infarction or ischemic stroke);\n• all venous thromboembolic events (including splanchnic vein thrombosis and cerebral vein thrombosis);\n• Quality of life (QoL) according to Anti-Clot Treatment Scale (ACTS) \nSafety Study Outcomes:\nPrimary safety outcome is major bleeding, defined (as per ISTH guidelines), as acute clinically overt bleeding associated with one or more of the following:\n• decrease in hemoglobin of 2 g/dl (1.2 mmol/L) or more;\n• transfusion of 2 or more units of packed red blood cells;\n• bleeding that occurs in at least one critical site [intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal];\n• bleeding that is fatal;\n• bleeding that necessitates acute surgical intervention\nSecondary safety outcomes include:\n• Clinically relevant non-major bleeding event defined as acute clinically overt bleeding that does not meet the criteria for major and consists of:\n• any bleeding compromising hemodynamics;\n• spontaneous hematoma larger than 25 cm2, or 100 cm2 if there was a traumatic cause;\n• intramuscular hematoma documented by ultrasonography;\n• epistaxis or gingival bleeding requiring tamponade or other medical intervention or bleeding from venipuncture for >5 minutes;\n• hematuria that was macroscopic and was spontaneous or lasted for more than 24 hours after invasive procedures;\n• hemoptysis, hematemesis or spontaneous rectal bleeding requiring endoscopy or other medical intervention;\n• or any other bleeding considered to have clinical consequences for a patient such as medical intervention,\nthe need for unscheduled contact (visit or telephone call) with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.\n• Clinically relevant bleeding defined as the composite of major and clinically relevant non-major bleeding\n• Permanent early discontinuation of study drug due to safety reasons\nMaximum Sample Size for each arm\nLess than 600 patients for each treatment group\nRecommended Inclusion Criteria\nAge > 18 years\nBoth Genders\nSigned Informed Consent\nConsecutive patients with a newly diagnosed, objectively\nconfirmed:\n• symptomatic or unsuspected, proximal lower-limb DVT\nor\n• symptomatic PE or\n• unsuspected PE in a segmental or more proximal pulmonary artery.\nAny type of cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or known intracerebral metastases and acute leukemia) that meets at least one of the\nfollowing:\n• Active cancer defined as diagnosis of cancer within six months before the study inclusion, or receiving treatment for cancer at the time of inclusion or any treatment for cancer during 6 months prior to randomization, or recurrent locally advanced or metastatic cancer.\n• Cancer diagnosed within 2 years before the study inclusion (history of cancer).\nRecommended Exclusion Criteria\nage <18 years\nECOG Performance Status III or IV;\nlife expectancy of less than 6 months;\nrelated to anticoagulant treatment:\nadministration of therapeutic doses of LMWH, fondaparinux, or unfractionated heparin (UFH) for more than 72 hours before randomization;\n3 or more doses of a vitamin K antagonist before randomization;\nthrombectomy, vena cava filter insertion, or thrombolysis used to manage the index episode;\n indication for anticoagulant treatment for a disease other than the index VTE episode;\nconcomitant use of strong inhibitors or inducers of both cytochrome P-450 3A4 and P-Glycoprotein ;\nrelated to bleeding risk:\nconcomitant thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) or aspirin over 165 mg daily or dual antiplatelet therapy;\nactive bleeding or high risk of bleeding contraindicating anticoagulant treatment\nrecent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery\n hemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count <75x109/L or history of heparin-induced thrombocytopenia;\ncreatinine clearance < 30 ml /min based on the Cockcroft Gault equation;\nacute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range;\nuncontrolled hypertension (systolic BP> 180 mm Hg or diastolic BP > 100 mm Hg despite antihypertensive treatment);\nstandard criteria:\n bacterial endocarditis;\nhypersensitivity to the study drugs or to any of their excipients;\npatients participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system.\nwomen of childbearing potential (WOCBP) who do not practice a medically accepted highly effective contraception during the trial and one month beyond. Highly effective contraception methods are:\na. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation\nb. progestogen-only hormonal contraception associated with inhibition of ovulation\nc. intrauterine device (IUD)\nd. intrauterine hormone-releasing system (IUS)\ne. bilateral tubal occlusion\nf. vasectomized partner\ng. sexual abstinence ;\npregnancy, or breast feeding\nany condition that, as judged by the investigator, would place the subject at increased risk of harm if he/she participated in the study.\n",
    "output": "## 5.1 Inclusion Criteria\n\nParticipants will be eligible to be included in the study only if all of the following criteria apply:\n## Age\nParticipant must be greater than 18 years of age.\n## Type of Participant and Disease Characteristics\nMust be a consecutive patient with a newly diagnosed, objectively confirmed:\nSymptomatic or unsuspected proximal lower-limb DVT, or\nSymptomatic PE, or\nUnsuspected PE in a segmental or more proximal pulmonary artery.\nMust have any type of cancer (excluding basal-cell or squamous-cell carcinoma of the skin,\nprimary brain tumor, known intracerebral metastases, and acute leukemia) that meets at\nleast one of the following criteria:\nActive Cancer:\nDiagnosis of cancer within six months before study inclusion, or\nreceiving treatment for cancer at the time of inclusion, or any treatment for cancer\nduring the 6 months prior to randomization, or recurrent locally advanced or metastatic\ncancer. Active cancer will also be defined as meeting any of the following criteria: (1)\nnonsquamous cell or basal cell invasive cancer diagnosed within 6 months before\nenrollment, (2) cancer treated within the previous 6 months, (3) recurrent or metastatic\ncancer, or (4) active cancer during the study.\nHistory of Cancer:\nCancer diagnosed within 2 years before study inclusion.\n## Weight\nNo specific weight or BMI criteria were provided in the source document.\n## Sex and Contraceptive/Barrier Requirements\nBoth male and female participants will be eligible. Contraceptive requirements for women of\nchildbearing potential are detailed in the exclusion criteria.\n## Informed Consent\nSigned informed consent as described in Appendix 1 which includes compliance with the\nrequirements and restrictions listed in the informed consent form (ICF) and in this protocol.",
    "context": "MANDATORY SPONSOR INPUTS FOR STUDY PROTOCOL GENERATION\nSponsor Name FADOI /BMS/PFIZER\nStudy Acronym (if available):  CARAVAGGIO Study\nTested IMP :Apixaban\nComparative drug: Dalteparin\nStudy Type Interventional\nSe Study Type = Interventional:\nInterventional Study Phase Phase IIIb\nStudy Design International, multicenter, Prospective Randomized Open Blinded End-point (PROBE), where both patients and investigators are aware of the treatment assignments, but the outcome assessment is blindedactive-controlled, event-driven, Phase IIIB clinical study comparing the efficacy and safety of Apixaban to the SOC Dalteparin in for the treatment of venous thromboembolism in patients with cancer.\nAim of the study: The aim of this study is to assess whether oral apixaban is non-inferior to the subcutaneous low molecular weight (LMWH) dalteparin for the treatment of newly diagnosed proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) in patients with cancer.\nTarget Disease: VTE (DVT/PE) in cancer patients\nType of Randomization: Patients will be randomized on a 1:1 basis (permuted blocks of four) to receive either apixaban or dalteparin in an open-label fashion.\nRandomization should be centralized and stratified by:\n1) symptomatic vs. unsuspected VTE\n2) active cancer vs. history of cancer\nTested drugs and dosages \nApixaban group: orally administered, at the dose of 10 mg bid for 7 days, followed by 5 mg bid (total period of treatment: six months)\nDalteparin group: subcutaneously administered, at a dose of 200 IU/kg SC o.i.d for 1 month. Thereafter, dalteparin will be administered at a dose of 150 IU/kg o.i.d. for 5 months (total period of treatment: six months). The maximum daily dose allowed for dalteparin is 18,000IU.\nApixaban 5mg will be supplied by the Promoter as film-coated tablets.\nDalteparin will be supplied by the Promoter as single-use pre-filled syringes.\nStudy Scheduled Patient’s Visits\nThe study should foresee the following scheduled visits: at enrollment, at 4 weeks, at 3 months, at 6 months, at the end of study treatment whenever it occurs, and at 7 months from randomization.\nAdditional visits will be performed if new symptoms and/or signs of VTE or major bleeding develop. A clinical examination and objective tests will be performed if the patient develops symptoms or signs suggestive of recurrent VTE.\nStudy Objectives \nPrimary efficacy outcome:\nobjectively confirmed recurrent VTE occurring during the study period, that means the composite of:\n• proximal DVT of the lower limbs (symptomatic or unsuspected)\n• DVT of the upper limb (symptomatic)\n• PE (symptomatic or unsuspected)\nSecondary efficacy outcomes:\n• the individual components of the primary efficacy outcome;\n• symptomatic recurrence of VTE;\n• all cause death;\n• the composite of primary efficacy outcome plus major bleeding;\n• the composite of primary efficacy outcome plus major bleeding plus all cause death;\n• the composite of primary efficacy outcome plus all cause death;\n• any major cardiovascular event, fatal or non-fatal (including acute myocardial infarction or ischemic stroke);\n• all venous thromboembolic events (including splanchnic vein thrombosis and cerebral vein thrombosis);\n• Quality of life (QoL) according to Anti-Clot Treatment Scale (ACTS) \nSafety Study Outcomes:\nPrimary safety outcome is major bleeding, defined (as per ISTH guidelines), as acute clinically overt bleeding associated with one or more of the following:\n• decrease in hemoglobin of 2 g/dl (1.2 mmol/L) or more;\n• transfusion of 2 or more units of packed red blood cells;\n• bleeding that occurs in at least one critical site [intracranial, intra-spinal, intraocular (within the corpus of the eye; thus, a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal];\n• bleeding that is fatal;\n• bleeding that necessitates acute surgical intervention\nSecondary safety outcomes include:\n• Clinically relevant non-major bleeding event defined as acute clinically overt bleeding that does not meet the criteria for major and consists of:\n• any bleeding compromising hemodynamics;\n• spontaneous hematoma larger than 25 cm2, or 100 cm2 if there was a traumatic cause;\n• intramuscular hematoma documented by ultrasonography;\n• epistaxis or gingival bleeding requiring tamponade or other medical intervention or bleeding from venipuncture for >5 minutes;\n• hematuria that was macroscopic and was spontaneous or lasted for more than 24 hours after invasive procedures;\n• hemoptysis, hematemesis or spontaneous rectal bleeding requiring endoscopy or other medical intervention;\n• or any other bleeding considered to have clinical consequences for a patient such as medical intervention,\nthe need for unscheduled contact (visit or telephone call) with a physician, or temporary cessation of a study drug, or associated with pain or impairment of activities of daily life.\n• Clinically relevant bleeding defined as the composite of major and clinically relevant non-major bleeding\n• Permanent early discontinuation of study drug due to safety reasons\nMaximum Sample Size for each arm\nLess than 600 patients for each treatment group\nRecommended Inclusion Criteria\nAge > 18 years\nBoth Genders\nSigned Informed Consent\nConsecutive patients with a newly diagnosed, objectively\nconfirmed:\n• symptomatic or unsuspected, proximal lower-limb DVT\nor\n• symptomatic PE or\n• unsuspected PE in a segmental or more proximal pulmonary artery.\nAny type of cancer (other than basal-cell or squamous-cell carcinoma of the skin, primary brain tumor or known intracerebral metastases and acute leukemia) that meets at least one of the\nfollowing:\n• Active cancer defined as diagnosis of cancer within six months before the study inclusion, or receiving treatment for cancer at the time of inclusion or any treatment for cancer during 6 months prior to randomization, or recurrent locally advanced or metastatic cancer.\n• Cancer diagnosed within 2 years before the study inclusion (history of cancer).\nRecommended Exclusion Criteria\nage <18 years\nECOG Performance Status III or IV;\nlife expectancy of less than 6 months;\nrelated to anticoagulant treatment:\nadministration of therapeutic doses of LMWH, fondaparinux, or unfractionated heparin (UFH) for more than 72 hours before randomization;\n3 or more doses of a vitamin K antagonist before randomization;\nthrombectomy, vena cava filter insertion, or thrombolysis used to manage the index episode;\n indication for anticoagulant treatment for a disease other than the index VTE episode;\nconcomitant use of strong inhibitors or inducers of both cytochrome P-450 3A4 and P-Glycoprotein ;\nrelated to bleeding risk:\nconcomitant thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) or aspirin over 165 mg daily or dual antiplatelet therapy;\nactive bleeding or high risk of bleeding contraindicating anticoagulant treatment\nrecent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery\n hemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count <75x109/L or history of heparin-induced thrombocytopenia;\ncreatinine clearance < 30 ml /min based on the Cockcroft Gault equation;\nacute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range;\nuncontrolled hypertension (systolic BP> 180 mm Hg or diastolic BP > 100 mm Hg despite antihypertensive treatment);\nstandard criteria:\n bacterial endocarditis;\nhypersensitivity to the study drugs or to any of their excipients;\npatients participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system.\nwomen of childbearing potential (WOCBP) who do not practice a medically accepted highly effective contraception during the trial and one month beyond. Highly effective contraception methods are:\na. combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation\nb. progestogen-only hormonal contraception associated with inhibition of ovulation\nc. intrauterine device (IUD)\nd. intrauterine hormone-releasing system (IUS)\ne. bilateral tubal occlusion\nf. vasectomized partner\ng. sexual abstinence ;\npregnancy, or breast feeding\nany condition that, as judged by the investigator, would place the subject at increased risk of harm if he/she participated in the study.\n"
}